Alternative myeloma-associated targets for immune-based therapy and strategies involving novel CAR T-cell constructs. CS1, CD2 subset 1; LC, light chain; MHC, major histocompatibility complex; NKG2DLs, NKG2D ligands; SLAMF7, signaling lymphocytic activation molecule family 7; TACI, transmembrane activator and CAML interactor; TCR, T-cell receptor.